Oncology Specimen Provider Reference Medicine Announces Launch of Characterized Specimens, Enabling Increased Speed and Efficiency for Assay Developers
Fulgent Genetics, Inc. (NASDAQ: FLGT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Fulgent Genetics, Inc. (NASDAQ: FLGT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Fulgent Genetics, Inc. (NASDAQ: FLGT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Fulgent Genetics, Inc. (NASDAQ: FLGT) had its price target lowered by analysts at Piper Sandler from $26.00 to $22.00. They now have a "neutral" rating on the stock.